Relapsing in Medical Technology

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis

- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting - CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc...

Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases

...d 15 to 44 years, depression is the most disabling medical illness in the United States. The prevalence of major depression, known to be a chronic and relapsing illness, is approximately 17 percent, affecting almost 1 in 5 persons. Medications and psychiatric therapy can effectively treat many patients wi...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

...ated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a ...N To Rebif New Formulation in Patients With Active relapsing Disease) study: a Phase II placebo-controlled tria...ding Cladribine Tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough dis...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

...one on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009. "Under the named patient program, CTI wi...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

... excellence have seen a dramatic rise in the incidence and diagnosis of EoE over the last decade. EoE tends to be a chronic disease with persistent or relapsing symptoms. The disease occurs when eosinophils, a type of white blood cell involved in allergic reactions, infiltrate the surface of the esophagus. Thi...

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

...Department of Neurology, Cologne City Hospitals, Germany. As previously reported, ATL/TV1102 significantly reduced disease activity in patients with relapsing Remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effec...

Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS

... initiated after the second clinical event or after two years, whichever occurs first. About Betaseron Betaseron is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated...

New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)

...y of life. The trial includes patients from 32 countries(ii) and is currently ongoing. About Betaseron Betaseron is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated...

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

... - the CLARITY Study - - for Treatment of relapsing Forms of Multiple Sclerosis GENEVA, Sept. 18 /PR...l trial - the CLARITY(1) study -- for treatment of relapsing forms of MS. As announced in January 2007, CLARITY...n beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 c...

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

...sability progression. Rebif(R) is currently approved for the treatment of relapsing forms of MS. It has been proven effective in all three key measures of trea...s or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. About Merck Serono Merck Serono is the...

Genmab Announces Upcoming Ofatumumab Studies

...b is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any ...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

...ntly authorized Alexion's Investigational New Drug application ("IND") for a clinical trial of ALXN6000 as a treatment for patients with refractory or relapsing B-cell Chronic Lymphocytic Leukemia ("CLL"). As previously announced, dosing in an open-label Phase I/II trial has commenced. Recruitment and dosing o...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...ing establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. "This patent represents an important component in the development of our intellectual property ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

... CD20 molecule. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any ...

Isis Pharmaceuticals Conference Call Notice

.../_home.asp to view the release titled: Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102, a Novel Drug for the Treatment of relapsing Remitting Multiple Sclerosis Demonstrated Significant Reduction in Disease Activity To access this call via telephone Please call 1-877-548-7901...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

...ments on bioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace Copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefi...

Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

... (radiolabelled immunotherapy) with 90Y-IT (90Y-ibritumomab tiuxetan) in relapsing FL (follicular lymphoma) after autologous (BM) bone marrow ...

Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit

... Medical Oncology (ESMO). "These final Phase 2 data show that picoplatin extended survival in patients with small cell lung cancer refractory to, or relapsing within 6 months of first-line platinum based chemotherapy," said Robert De Jager, M.D., chief medical officer of Poniard. "Based on promising results ...

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

... began with a six-month placebo-controlled phase in which 281 patients with relapsing MS received placebo, FTY720 1.25 mg or FTY720 5 mg once-daily. This was fol...h, vision, balance, sensation and mental function. MS typically presents in relapsing forms involving acute self-limiting attacks of neurological dysfunction (or...

Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis

...n's lymphoma (NHL) is near completion. "Despite the availability of newer biologic agents, drugs such as mitoxantrone remain an important therapy in relapsing MS. Long term cardiotoxicity remains a major drawback to treating multiple sclerosis with mitoxantrone and imposes a limitation both for selection of ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... Phase I/II Study of Rituxan in Combination with DOXIL in Patients with relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxici... Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients relapsing within 12 Months of Stem Cell Transplant - Shaji Kumar, Mayo Clinic, Ro...

Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies

...esearchers noted a significant improvement in overall survival for patients relapsing after 2000, compared with those relapsing before 2000 (24 vs. 12 months). Patients relapsing before 2000 were less likely to receive a prompt transplant and more likely...

Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month

...ioid dependence. Reckitt Benckiser Pharmaceuticals Inc. is committed to expanding access to medical therapies for patients suffering from the chronic, relapsing brain disease of opioid dependence. For more information, visit suboxone.com or opioiddependence.com. Reckitt Benckiser Pharmaceuticals Inc. is a whol...

Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression

...s at the first clinical sign of MS to delay the accumulation of disability." "We now see real hope for changing the course of disease progression for relapsing MS if people with the disease start an effective treatment like Betaseron right away, rather than wait for further clinical signs of MS to occur," sai...

MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial

...a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS). The randomized, double-blind, placebo-controlled trial showed a significant increase in the proportion of patients who rema...

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

...ow-up therapy. About AVONEX AVONEX is the most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVON...

Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability

...g drug introduced for MS and is a well-established treatment around the world. In the U.S., Europe and Japan, Betaferon® has been approved for all relapsing forms of MS. It is able to reduce the number of MS episodes by one-third, and the frequency of moderate to severe episodes by as much as 50 percent. S...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...cy of relapses and the sustained accumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Rebif(R) (interfer...urse of MS is highly variable, but is typically characterized by an initial relapsing and remitting phase where episodes of transient neurological compromise are...

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

...Term Follow-up (16- Year LTF) Study(3)- found long-term(4) use of Betaseron to be safe and tolerable. The 16-Year LTF Study followed patients with the relapsing form of MS who had already participated in the pivotal Betaseron trial, the results of which led to the drug's approval in 1993. The long-term use of ...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

...g-term Glatiramer Acetate (GA) Are Maintained at 24 Months in Patients with relapsing Remitting Multiple Sclerosis (RRMS), determined that the increased efficacy...tate Following a Brief and Low Dose Course of Mitoxantrone in Patients with relapsing Remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

...g-term Glatiramer Acetate (GA) Are Maintained at 24 Months in Patients with relapsing Remitting Multiple Sclerosis (RRMS), determined that the increased efficacy...tate Following a Brief and Low Dose Course of Mitoxantrone in Patients with relapsing Remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on ...

Data to be presented at AAN Meeting -Study results of drug candidate for MS

...gram as a once-daily disease modifying therapy for relapsing MS EAST HANOVER, NJ, May 3, 2007 - New preclinic...tion and mental function. MS typically presents in relapsing forms involving acute self-limiting attacks of neu...ram as a once-daily, disease modifying therapy for relapsing MS. Previously reported Phase II results showed th...

Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis

...ars. This study confirms that early treatment is desirable in MS to avoid or diminish long-term disability. Betaseron is approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. Patients with MS in whom efficacy has been demonstrated include patients who have exper...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

...linical trial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis (MS). In this one-year, 8-subject extension clinical trial of relapsing remitting (RRMS) and secondary progressive (SPMS) subjects, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin...